Debulking Surgery: Interval Debulking Surgery Versus Primary: Pros and Cons on How to Evaluate Quality

[1]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[2]  Austin Miller,et al.  Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Huttenhower,et al.  Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. , 2014, Journal of the National Cancer Institute.

[4]  Jaime Prat,et al.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[5]  P. Bossuyt,et al.  Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. , 2013, European journal of cancer.

[6]  P. Morice,et al.  Multi-Center Evaluation of Post-Operative Morbidity and Mortality after Optimal Cytoreductive Surgery for Advanced Ovarian Cancer , 2012, PloS one.

[7]  R. Ozols,et al.  The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. , 2011, Gynecologic oncology.

[8]  R. Rouzier,et al.  Morbidity of diaphragmatic surgery for advanced ovarian cancer: retrospective study of 148 cases. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[10]  D. Levine,et al.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. , 2009, Gynecologic oncology.

[11]  Jacobus Pfisterer,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[12]  Jacobus Pfisterer,et al.  Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. , 2009, Gynecologic oncology.

[13]  I Vergote,et al.  Timing of debulking surgery in advanced ovarian cancer , 2008, International Journal of Gynecologic Cancer.

[14]  R. Barakat,et al.  The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. , 2008, Gynecologic oncology.

[15]  Y. van der Graaf,et al.  The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. , 2007, Gynecologic oncology.

[16]  D. Levine,et al.  What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC) , 2006 .

[17]  W. Cliby,et al.  Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. , 2006, Journal of the American College of Surgeons.

[18]  S. Rubin,et al.  Secondary surgical cytoreduction for advanced ovarian carcinoma. , 2004, The New England journal of medicine.

[19]  D. Levine,et al.  Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. , 2004, Gynecologic oncology.

[20]  N. Spirtos,et al.  Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. , 2003, Gynecologic oncology.

[21]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis , 2002 .

[22]  N. Spirtos,et al.  Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? , 2001, Gynecologic oncology.

[23]  M. Buyse,et al.  The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.

[24]  I. Vergote,et al.  Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? , 2013, Gynecologic oncology.